Onglyza

Onglyza (generic name Saxagliptin) was first approved for use in the United States in 2008. The product, marketed by Bristol-Myers Squibb, is an oral hypoglycemic, designed to be used by itself or in conjunction with other pharmaceutical products to treat type 2, or adult onset, diabetes.

Over the last few years, however, Saxagliptin has repeatedly been linked to a number of serious side effects, including anaphylactic shock, acute pancreatitis and upper respiratory tract infection. In 2014, the FDA launched an investigation of the health risks of the drug after receiving reports of higher than normal fatal heart attacks among users. The FDA’s investigation found that individuals who used Onglyza had a 27% higher risk of heart failure than those not using the product. In April, 2016, the FDA issued an additional warning regarding the elevated risk of heart failure for patients using Onglyza.

Onglyza users have also reported alarming rates of pancreatic and thyroid cancer. As a result, the FDA has requested warnings to appear on the drug’s label, referring to the cancer and cardiac risks.

If you or someone you love has suffered injury after taking Onglyza, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory.